We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Asthma Drug Blocks Plaque Formation in Mouse Model of Alzheimer's Disease

By LabMedica International staff writers
Posted on 07 Apr 2011
Print article
The drug zileuton, which is used to treat asthma, has been shown to reduce formation of amyloid plaques in an Alzheimer's disease mouse model.

Investigators at Temple University (Philadelphia, PA, USA) had found previously that plaque formation required the activity of the enzyme gamma secretase and that gamma secretase was regulated in turn by another enzyme, 5-lipoxygenase. The latter enzyme is inhibited by zileuton, and in the current study, the investigators examined what effect the drug might have on amyloid plaque formation in the Tg2576 transgenic mouse model of Alzheimer's disease.

They reported in the April 2011 issue of the American Journal of Pathology that amyloid-beta deposition in the brains of mice receiving zileuton was significantly reduced when compared with control Tg2576 mice receiving a placebo. This reduction was associated with a similar decrease in brain amyloid-beta peptides levels. Zileuton treatment did not induce any change in the steady state levels of amyloid-beta precursor protein, but rather it resulted in a significant reduction in levels of the four components of the gamma secretase complex. These findings were confirmed by in vitro studies that showed that zileuton prevented amyloid-beta formation by modulating gamma secretase-complex levels.

Zileuton has already been approved by the [US] FDA (Food and Drugs Administration) for treatment of asthma through 5-lipoxygenase inhibition. Blocking this enzyme has not been associated with overt toxicity and it was well tolerated by patients.

"This drug is already on the market and, most importantly, is already FDA-approved, so you do not need to go through an intense drug discovery process,” said senior author Dr. Domenico Praticò, associate professor of pharmacology at Temple University. "So we could quickly begin a clinical trial to determine if there is a new application for this drug against a disease where there is currently nothing.”

Related Links:
Temple University



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Thyroid ELISA Kit
AESKULISA a-TPO
New
Automated Nucleic Acid Extractor
eLab

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The artificial intelligence models can personalize immune therapies in oncology patients (Photo courtesy of 123RF)

AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.